| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
8-Bromoadenosine targets guanine nucleotide-binding proteins (G proteins) and has been shown to inhibit their activity. The compound also inhibits the mitochondrial membrane potential, cytosolic Ca2+, and the synthesis of RNA and protein. As an adenosine analog, it may also interact with adenosine receptors or affect adenosine metabolism.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, 8-Bromoadenosine is used to study nucleic acid structure and function. The compound is an adenosine binding inhibitor. It has been shown to inhibit the mitochondrial membrane potential and the synthesis of RNA and protein in cell-free systems. The compound can also be used to investigate interactions between nucleic acids and proteins.
|
| ln Vivo |
In cell-based assays, 8-Bromoadenosine exhibits biological properties including inhibition of guanine nucleotide-binding proteins. The compound has been shown to inhibit the mitochondrial membrane potential and cytosolic Ca2+. Adenosine analogs mostly work as smooth muscle vasodilators and have also been found to suppress cancer progression.
|
| Enzyme Assay |
The cell-free assay for studying 8-Bromoadenosine typically involves measuring its effects on nucleic acid structure or protein-nucleic acid interactions. The compound can be used in gel shift assays, footprinting experiments, or other biochemical techniques to study nucleic acid-protein interactions. The inhibition of guanine nucleotide-binding proteins can be assessed in cell-free systems using GTPase activity assays.
|
| Cell Assay |
Cell-based assays for 8-Bromoadenosine involve culturing mammalian cells and treating them with the compound at concentrations ranging from 0.1 to 100 μM. The effect on mitochondrial membrane potential is assessed using fluorescent dyes such as JC-1 or TMRE. Cytosolic Ca2+ levels are measured using calcium-sensitive fluorescent dyes. RNA and protein synthesis are assessed by incorporation of labeled precursors.
|
| Animal Protocol |
There is no established animal experimental protocol for 8-Bromoadenosine specifically. As an adenosine analog, the compound could potentially be evaluated in animal models for its effects on cardiovascular function, inflammation, or cancer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 8-Bromoadenosine have not been extensively reported. As a small molecule with molecular weight of 346.14 g/mol, the compound would be expected to have reasonable bioavailability and tissue penetration. The presence of the bromine atom may affect the compound's metabolic stability. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
Toxicity data for 8-Bromoadenosine are not well documented. As an adenosine analog, the compound may have effects on cardiovascular function. Standard toxicity studies would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
8-Bromide adenosine is a purine nucleoside.
8-Bromoadenosine is a research compound used to study nucleic acid structure and function, and to investigate interactions between nucleic acids and proteins. The compound is an adenosine binding inhibitor and has been shown to inhibit guanine nucleotide-binding proteins. It also inhibits mitochondrial membrane potential, cytosolic Ca2+, and RNA and protein synthesis. It is not an approved pharmaceutical and has no clinical trial history. This product is intended for research use only. |
| Molecular Formula |
C10H12BRN5O4
|
|---|---|
| Molecular Weight |
346.14
|
| Exact Mass |
345.007
|
| CAS # |
2946-39-6
|
| PubChem CID |
96544
|
| Appearance |
Solid powder
|
| Density |
2.5±0.1 g/cm3
|
| Boiling Point |
717.7±70.0 °C at 760 mmHg
|
| Melting Point |
210-212 °C (dec.)(lit.)
|
| Flash Point |
387.8±35.7 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.941
|
| LogP |
-0.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=C2C(=N1)N(C(=N2)Br)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
|
| InChi Key |
VJUPMOPLUQHMLE-UUOKFMHZSA-N
|
| InChi Code |
InChI=1S/C10H12BrN5O4/c11-10-15-4-7(12)13-2-14-8(4)16(10)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,13,14)/t3-,5-,6-,9-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-(6-amino-8-bromopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8890 mL | 14.4450 mL | 28.8900 mL | |
| 5 mM | 0.5778 mL | 2.8890 mL | 5.7780 mL | |
| 10 mM | 0.2889 mL | 1.4445 mL | 2.8890 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
